Research Analysts Set Expectations for CervoMed Q1 Earnings

CervoMed Inc. (NASDAQ:CRVO) – Stock analysts at Brookline Capital Markets issued their Q1 2026 earnings per share (EPS) estimates for shares of CervoMed in a report released on Friday, May 15th. Brookline Capital Markets analyst F. Ahmed anticipates that the company will post earnings of ($0.86) per share for the quarter. The consensus estimate for CervoMed’s current full-year earnings is ($2.31) per share. Brookline Capital Markets also issued estimates for CervoMed’s Q2 2026 earnings at ($0.98) EPS, Q3 2026 earnings at ($1.04) EPS, Q4 2026 earnings at ($1.55) EPS and FY2026 earnings at ($4.34) EPS.

CervoMed (NASDAQ:CRVO) last posted its quarterly earnings data on Friday, May 15th. The company reported ($0.86) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.79) by ($0.07). CervoMed had a negative net margin of 672.80% and a negative return on equity of 116.01%.

CRVO has been the subject of several other reports. Chardan Capital upped their target price on CervoMed from $15.00 to $21.00 and gave the stock a “buy” rating in a report on Wednesday, March 18th. Roth Mkm set a $9.00 target price on CervoMed in a report on Monday. D. Boral Capital reiterated a “buy” rating and issued a $31.00 target price on shares of CervoMed in a report on Wednesday, April 22nd. upgraded CervoMed to a “strong-buy” rating in a report on Tuesday, February 3rd. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of CervoMed in a report on Monday, April 20th. Six equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, CervoMed currently has a consensus rating of “Moderate Buy” and an average target price of $22.60.

CervoMed Trading Down 11.6%

Shares of CRVO stock opened at $3.04 on Tuesday. CervoMed has a twelve month low of $2.89 and a twelve month high of $13.13. The stock has a market capitalization of $28.15 million, a price-to-earnings ratio of -0.93 and a beta of -0.63. The stock has a fifty day simple moving average of $3.97 and a two-hundred day simple moving average of $5.90.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of the company. Renaissance Technologies LLC acquired a new position in shares of CervoMed in the first quarter valued at about $252,000. XTX Topco Ltd acquired a new position in shares of CervoMed in the fourth quarter valued at about $81,000. State Street Corp increased its holdings in shares of CervoMed by 11.4% in the fourth quarter. State Street Corp now owns 20,527 shares of the company’s stock valued at $162,000 after purchasing an additional 2,100 shares during the period. Jane Street Group LLC acquired a new position in shares of CervoMed in the fourth quarter valued at about $88,000. Finally, HRT Financial LP acquired a new position in shares of CervoMed in the fourth quarter valued at about $113,000. 25.15% of the stock is owned by institutional investors and hedge funds.

About CervoMed

CervoMed Inc, a biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. Its lead drug candidate is neflamapimod, an orally administered small molecule brain penetrant for the treatment of dementia with Lewy bodies (DLB), Alzheimer's diseases, frontotemporal dementia, and ischemic stroke recovery. The company also develops EIP200 for central nervous system which is in preclinical trials. CervoMed Inc was founded in 2010 and is headquartered in Boston, Massachusetts.